We are delighted to announce that Sandra Johnson will join Richmond Pharmacology as its new Director for Commercial Project Management, focused on enhancing the company’s procurement and outsourcing functions.  Sandra joined Richmond Pharmacology in September 2022 from Medicines for Malaria Venture and will work alongside the company’s senior management team and CEO, Dr Jorg Taubel, to improve procurement and outsourcing to further enhance first-in-human and adaptive clinical trials.

Sandra has over 20 years of experience in the life science sector, including at Roche and Novartis, and she has an extensive understanding of clinical procurement. During her time at Medicines for Malaria Venture, she was Director for Outsourcing & Relationship Management. Prior to this, Sandra served as Outsourcing and Procurement Consultant at Minerve Services, and before that as Team Leader Procurement, Global Product Strategy at Roche and Senior CRO Manager at Novartis, where she outsourced clinical research services for Phase I-IV trials and oversaw its strategic outsourcing initiative.

Sandra is currently a member of the Global Health Clinical Consortium and the Pharmaceutical Contracts Management Group (PCMG).

Please join us in welcoming Sandra in our team!

Latest news

Futureproofing early phase clinical research for the next generation of investigators.

March 20, 2023
Richmond Pharmacology’s experienced Principal investigators and Co-investigators recently gave expert feedback on the ICH M11 (CeSHarP) protocol template.
Read more

Director of Operations, Keith Berelowitz, has been appointed as the Research Ethics Committee Chair for the Health Research Authority.

January 19, 2023
Keith Berelowitz will be responsible for ensuring that all ethical possibilities are explored in relation to new research.
Read more


13th International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions

Sunday, June 4th to Tuesday June 6th 2023
Exchange research-based knowledge on drug-drug interactions (DDIs) among all interested stakeholders from pharmaceutical industry, regulatory authorities, academic and health care delivery backgrounds and perspectives.
View event